Advertisement

Topics

BioPortfolio Blog about Biotechnology, Pharmaceutical and Healthcare

08:21 EDT 28th July 2016 | BioPortfolio

Updates and info from the contributors bringing you BioPortfolio.com.

Showing News Articles 1–5 of 1,400+

Thursday 28th July 2016

Amgen Raises 2016 Forecast as Profit Beats Analyst Estimates

Biotechnology giant Amgen Inc.'s second-quarter profit beat analysts' estimates, driven by higher-than-expected drug sales, and the company raised its guidance for the year. Earnings excluding one-time items totaled $2.84 a share, Amgen said Wednesday in a statement, topping the $2.74 average of analysts' projections compiled by Bloomberg.

Wednesday 27th July 2016

Bayer Second-Quarter Profit Gains 5.7% Amid Monsanto Pursuit

Bayer AG, the German chemicals company seeking to acquire Monsanto Co., reported a 5.7 percent increase in second-quarter profit as prescription-drug sales helped offset weakness in its crop sciences and consumer health units. Earnings before interest, taxes, depreciation and amortization, and excluding some costs, climbed to 3.05 billion euros , the Leverkusen, Germany-based company said in a sta...

Teva purchase of Allergan generics business approved with conditions

Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest more than 75 generic drugs to rival firms, the Federal Trade Commission said on Wednesday. The $40.5 billion deal, which was announced in July 2015, solidifies Teva's position as the world's No.

Angus MP welcomes Glaxo's Montrose investment

Congratulations, you're now registered! Let us know what news and updates you want to hear about and we'll send them straight to your inbox. Angus MP Mike Weir has welcomed the announcement from GlaxoSmithKline of a new investment in its facilities at Montrose as part of a wider investment in the UK.

Long-time Lilly CEO Lechleiter to retire in December

Eli Lilly Chairman and CEO John C. Lechleiter will retire in December after leading the drugmaker through a challenging period in which it lost U.S. patent protection for several top-selling products. The Indianapolis company says the president of its bio-medicines business, David A. Ricks, will replace Lechleiter as CEO in January and become board chairman next June.


Quick Search
Advertisement